Company intelligence / Profile preview

Vortex Biosciences

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Vortex Biosciences has developed and commercialized the VTX-1 Liquid Biopsy System, which automates the isolation of circulating tumor cells from blood samples. This enables noninvasive cancer diagnosis and real-time monitoring throughout treatment. The system is used for patient stratification in clinical trials, disease progression monitoring, and evaluating drug effectiveness. No clinical trial results are reported as it is a diagnostic platform rather than a therapeutic product.

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic toolMicrofluidic technology
Industry: Molecular Diagnostics

Partnerships

BioView Ltd.

Beyond the preview

Go deeper on Vortex Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vortex Biosciences.

Explore the full profile